NEW YORK, NY / ACCESSWIRE / November 4, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Odonate Therapeutics, Inc. (NASDAQ:ODT)
Class Period: December 7, 2017 - April 21, 2020
Lead Plaintiff Deadline: November 16, 2020
The ODT lawsuit alleges that throughout the class period, Odonate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in ODT: http://www.kleinstocklaw.com/pslra-1/odonate-therapeutics-inc-loss-submission-form?id=10711&from=1
First American Financial Corp. (NYSE:FAF)
Class Period: February 17, 2017 - October 22, 2020
Lead Plaintiff Deadline: December 24, 2020
The complaint alleges that during the class period First American Financial Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company failed to implement basic security standards to protect its customers' sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in FAF: http://www.kleinstocklaw.com/pslra-1/first-american-financial-corp-loss-submission-form?id=10711&from=1
Zosano Pharma Corporation (NASDAQ:ZSAN)
Class Period: February 13, 2017 - September 30, 2020
Lead Plaintiff Deadline: December 28, 2020
The ZSAN lawsuit alleges that throughout the class period, Zosano Pharma Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in ZSAN: http://www.kleinstocklaw.com/pslra-1/zosano-pharma-corporation-loss-submission-form?id=10711&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: